Selected Publications

Academic Article

Year Title Altmetric
2019 Myocardial blood flow measures using cardiac positron emission tomography: Software comparisons 2019
2019 Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Workflow for Research and Clinical Brain PET Applications 2019
2019 Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0 2019
2019 Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical Center 2019
2018 Imaging melphalan therapy response in preclinical extramedullary multiple myeloma with 18F-FDOPA and 18F-FDG PET 2018
2018 Investigational PET tracers for high-grade gliomas 2018
2018 Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer 2018
2018 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors 2018
2018 PET/MR Imaging in Head and Neck Cancer: Current Applications and Future Directions 2018
2018 Amino acid uptake measured by [ 18 F]AFETP increases in response to arginine starvation in ASS1-deficient sarcomas 2018
2018 Measurement of blood flow in myocardial layers: A step toward comprehensive physiological evaluation 2018
2018 Practical Considerations for Clinical PET/MR Imaging 2018
2017 Lymph node imaging in initial staging of prostate cancer: An overview and update. 2017
2017 ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. 2017
2017 Evaluation of attenuation correction in cardiac PET using PET/MR 2017
2017 Practical Considerations for Clinical PET/MR Imaging 2017
2017 Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. 2017
2017 Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. 2017
2016 Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make? 2016
2016 18F-Fluciclovine (FACBC) and its potential use for breast cancer imaging 2016
2016 Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis. 2016
2016 Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. 2016
2016 Clinical application of PET/MRI in oncology 2016
2016 Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma 2016
2016 SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. 2016
2016 The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging 2016
2016 Multimodality Review of Amyloid-related Diseases of the Central Nervous System. 2016
2016 Impact of MR-Based Attenuation Correction on Neurologic PET Studies. 2016
2016 Effect of α-Methyl versus α-Hydrogen Substitution on Brain Availability and Tumor Imaging Properties of Heptanoic [F-18]Fluoroalkyl Amino Acids for Positron Emission Tomography (PET) 2016
2016 PET/MRI: Emerging Clinical Applications in Oncology. 2016
2015 Synthesis and Biological Evaluation of (S)-Amino-2-methyl-4-[76Br]bromo-3-(E)-butenoic Acid (BrVAIB) for Brain Tumor Imaging 2015
2015 PET/MRI for the body imager: abdominal and pelvic oncologic applications. 2015
2015 Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors. 2015
2015 Imaging biomarkers associated with cognitive decline: a review. 2015
2015 American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. 2015
2015 Beyond whole-body imaging: Advanced imaging techniques of PET/MRI 2015
2015 Facile purification and click labeling with 2-[18F]fluoroethyl azide using solid phase extraction cartridges. 2015
2015 Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. 2015
2015 System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid. 2015
2014 Attenuation Effects of MR Headphones During Brain PET/MR Studies. 2014
2014 An overview of nuclear medicine studies for urgent and emergent indications. 2014
2014 Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study 2014
2014 Whole-body simultaneous positron emission tomography (PET)-MR: optimization and adaptation of MRI sequences. 2014
2014 Imaging evaluation of CSF shunts. 2014
2013 Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET 2013
2013 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas. 2013
2013 Radiolabeled amino acids for oncologic imaging. 2013
2013 Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging. 2013
2013 Overview of PET Tracers for Brain Tumor Imaging. 2013
2013 Nuclear medicine in the acute clinical setting: indications, imaging findings, and potential pitfalls. 2013
2013 Advances in diagnostic testing for Alzheimer disease. 2013
2013 Fluorine-18 labeled amino acids for oncologic imaging with positron emission tomography. 2013
2012 Commentary. 2012
2012 Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. 2012
2010 Click synthesis and biologic evaluation of (R)- and (S)-2-amino-3-[1-(2-[18F]fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid for brain tumor imaging with positron emission tomography. 2010
2010 Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors. 2010
2008 Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. 2008
2007 Preparation of antidepressants for use in preclinical research. 2007
2006 Evaluation of carbon-11-labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET. 2006
2005 Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies. 2005
2005 Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. 2005
2005 Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands. 2005
2005 Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. 2005
2004 Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. 2004
2004 Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. 2004
2003 Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids. 2003
2003 Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. 2003
2003 Stereochemistry in Drug Action. 2003
2003 Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography. 2003
2002 Radiolabeled amino acids for tumor imaging with PET: radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid. 2002
2002 Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection. 2002
2001 Radioligands for PET and SPECT Imaging of the central noradrenergic system. 2001


Year Title Altmetric
2018 PET/MRI for clinical pediatric oncologic imaging.  401-432. 2018
2017 Overview of positron-emission tomography tracers for metabolic imaging.  47-80. 2017

Investigator On

  • Measuring Neuroinflammation in Chronic Fatigue Syndrome with Whole-brain Magnetic Resonance Spectroscopy  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2019 - 2024
  • Personalizing Immunotherapy in HER2+ Breast Cancer through Quantitative Imaging  awarded by National Cancer Institute/NIH/DHHS 2020 - 2024
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: Role of Innate Immune Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Detecting Neuroinflammation in Fibromyalgia with the Positron Emission Tomography (PET) Radioligand [18] DPA-714  awarded by American Fibromyalgia Syndrome Association 2019 - 2021
  • Viability Testing of Immune Cells Extracted from Human Blood Samples  awarded by ME RESEARCH UK 2019 - 2020
  • Radiolabeled Antibodies Targeting LAT1 for Imaging and Therapy of Prostate Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2018 - 2019
  • Private Grant  awarded by NAVIDEA BIOPHARMACEUTICALS, INC. 2017 - 2019
  • Education And Training

  • Doctor of Medicine, Emory University 2004
  • Doctor of Philosophy in Biological and Biomedical Sciences, Emory University 2003
  • Emory University SOM, Internship 2005
  • Washington University SOM, Residency 2009
  • Washington University SOM, Postdoctoral Fellowship 2010
  • Full Name

  • Jonathan McConathy